Literature DB >> 24897277

Warfarin pharmacogenetic trials: is there a future for pharmacogenetic-guided dosing?

Stuart A Scott1, Steven A Lubitz.   

Abstract

Entities:  

Keywords:  CYP2C9; VKORC1; clinical utility; pharmacogenetics; pharmacogenomics; randomized controlled clinical trial; warfarin

Mesh：

Substances：

Year:  2014        PMID： 24897277      PMCID： PMC4110075          DOI： 10.2217/pgs.14.18

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


× No keyword cloud information.
  19 in total

1.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2003-05-07       Impact factor: 24.094

2.  Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans.

Authors:  W Hernandez; E R Gamazon; K Aquino-Michaels; S Patel; T J O'Brien; A F Harralson; R A Kittles; A Barbour; M Tuck; S D McIntosh; J N Douglas; D Nicolae; L H Cavallari; M A Perera
Journal:  Pharmacogenomics J       Date:  2013-09-10       Impact factor: 3.550

3.  Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).

Authors:  Robert S Epstein; Thomas P Moyer; Ronald E Aubert; Dennis J O Kane; Fang Xia; Robert R Verbrugge; Brian F Gage; J Russell Teagarden
Journal:  J Am Coll Cardiol       Date:  2010-04-08       Impact factor: 24.094

4.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.

Authors:  Mark J Rieder; Alexander P Reiner; Brian F Gage; Deborah A Nickerson; Charles S Eby; Howard L McLeod; David K Blough; Kenneth E Thummel; David L Veenstra; Allan E Rettie
Journal:  N Engl J Med       Date:  2005-06-02       Impact factor: 91.245

5.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

6.  Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation.

Authors:  Jeffrey L Anderson; Benjamin D Horne; Scott M Stevens; Amanda S Grove; Stephanie Barton; Zachery P Nicholas; Samera F S Kahn; Heidi T May; Kent M Samuelson; Joseph B Muhlestein; John F Carlquist
Journal:  Circulation       Date:  2007-11-07       Impact factor: 29.690

7.  The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors:  Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

8.  Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.

Authors:  B F Gage; C Eby; J A Johnson; E Deych; M J Rieder; P M Ridker; P E Milligan; G Grice; P Lenzini; A E Rettie; C L Aquilante; L Grosso; S Marsh; T Langaee; L E Farnett; D Voora; D L Veenstra; R J Glynn; A Barrett; H L McLeod
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

9.  A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Authors:  Fumihiko Takeuchi; Ralph McGinnis; Stephane Bourgeois; Chris Barnes; Niclas Eriksson; Nicole Soranzo; Pamela Whittaker; Venkatesh Ranganath; Vasudev Kumanduri; William McLaren; Lennart Holm; Jonatan Lindh; Anders Rane; Mia Wadelius; Panos Deloukas
Journal:  PLoS Genet       Date:  2009-03-20       Impact factor: 5.917

10.  Estimation of the warfarin dose with clinical and pharmacogenetic data.

Authors:  T E Klein; R B Altman; N Eriksson; B F Gage; S E Kimmel; M-T M Lee; N A Limdi; D Page; D M Roden; M J Wagner; M D Caldwell; J A Johnson
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245
View more
  11 in total

1.  Implementing Algorithm-Guided Warfarin Dosing in an Ethnically Diverse Patient Population Using Electronic Health Records and Preemptive CYP2C9 and VKORC1 Genetic Testing.

Authors:  A Owusu Obeng; T Kaszemacher; N S Abul-Husn; O Gottesman; A Vega; E Waite; K Myers; J Cho; E P Bottinger; S B Ellis; S A Scott
Journal:  Clin Pharmacol Ther       Date:  2016-08-18       Impact factor: 6.875

2.  STRATEGIES FOR EQUITABLE PHARMACOGENOMIC-GUIDED WARFARIN DOSING AMONG EUROPEAN AND AFRICAN AMERICAN INDIVIDUALS IN A CLINICAL POPULATION.

Authors:  Laura K Wiley; Jacob P Vanhouten; David C Samuels; Melinda C Aldrich; Dan M Roden; Josh F Peterson; Joshua C Denny
Journal:  Pac Symp Biocomput       Date:  2017

3.  Genes affecting warfarin response-interactive or additive?

Authors:  Larisa H Cavallari; Julio D Duarte
Journal:  J Clin Pharmacol       Date:  2014-12-30       Impact factor: 3.126

4.  Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans.

Authors:  Katarzyna Drozda; Shan Wong; Shitalben R Patel; Adam P Bress; Edith A Nutescu; Rick A Kittles; Larisa H Cavallari
Journal:  Pharmacogenet Genomics       Date:  2015-02       Impact factor: 2.089

5.  Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study.

Authors:  Gary E Marchant; Kathryn Scheckel; Doug Campos-Outcalt
Journal:  J Law Med Ethics       Date:  2016-03       Impact factor: 1.718

6.  Revisiting Warfarin Dosing Using Machine Learning Techniques.

Authors:  Ashkan Sharabiani; Adam Bress; Elnaz Douzali; Houshang Darabi
Journal:  Comput Math Methods Med       Date:  2015-06-04       Impact factor: 2.238

Review 7.  Closing the gap between knowledge and clinical application: challenges for genomic translation.

Authors:  Wylie Burke; Diane M Korngiebel
Journal:  PLoS Genet       Date:  2015-02-26       Impact factor: 5.917

8.  Other side of the coin for personalised medicine and healthcare: content analysis of 'personalised' practices in the literature.

Authors:  Tomris Cesuroglu; Elena Syurina; Frans Feron; Anja Krumeich
Journal:  BMJ Open       Date:  2016-07-13       Impact factor: 2.692

Review 9.  A path to precision in the ICU.

Authors:  David M Maslove; Francois Lamontagne; John C Marshall; Daren K Heyland
Journal:  Crit Care       Date:  2017-04-03       Impact factor: 9.097

10.  Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation.

Authors:  Xi Zhang; Guang-Yu Chen; Zhao-Xia Wang; Xue-Hai Li; Rong Luo; Yi-Gang Li; Fan Yang; Xin Zhou; Feng Jiang; Yao-Sheng Wang
Journal:  Ann Transl Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.